GLP-1 Weight Loss Medication
Physician review · Free delivery · Cancel anytime
STEP 1 Trial (2021) · 1,961 participants · 68 weeks
Average body weight reduction at 68 weeks. Bars scaled to 25% max. Individual results vary.
Ozempic (brand-name semaglutide) demonstrated statistically significant, clinically meaningful weight loss vs. placebo in the STEP 1 trial. Participants followed a reduced-calorie diet and increased physical activity alongside treatment.
Important: The clinical trial data above refers to Ozempic, the FDA-approved brand-name semaglutide. Compounded semaglutide has not been studied in clinical trials and has not been approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded medications are prepared by licensed pharmacies under FDA oversight of pharmacy practices, but the compounded formulation itself is not FDA-approved.
GLP-1 Receptor Agonist
Mimics GLP-1, a hormone naturally released after eating, signaling fullness to the brain and reducing appetite†
Slows gastric emptying so you feel satisfied longer after meals — reducing overall caloric intake†
Acts on hunger centers in the hypothalamus to reduce food cravings between meals†
Improves insulin sensitivity and helps regulate blood sugar, supporting metabolic health beyond weight loss†
†These statements have not been reviewed by the FDA.
Your clinician may adjust timing based on your individual response and tolerability.
Starter dose — lets your body adjust with minimal GI side effects
Building tolerance; early appetite-suppressing effects begin
Active therapeutic range — most patients notice meaningful changes
Enhanced efficacy phase; continued weight loss acceleration
Full dose — maximum weight loss benefit sustained
All dosages included in your monthly price. You will not be charged more as your dose increases through the titration schedule.
The standard titration schedule is designed to maximise weight loss in patients following a reduced-calorie diet. The microdosing protocol is a separate application — a single low dose held flat throughout treatment, calibrated for active individuals who want metabolic and recovery benefits without significant appetite suppression.
Flat weekly dose
0.125 mg/week
Dose comparison
Relative dose only. Not to clinical scale.
You pay the same from your first starter dose through maintenance. No surprise charges as your dose increases.
Complete a free intake. A licensed physician reviews your profile within 48 hours.
Start Semaglutide Intake →No credit card required to start
